RedHill Biopharma Files 2024 Annual Report
Ticker: RDHL · Form: 20-F · Filed: Apr 10, 2025 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 20-F |
| Filed Date | Apr 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, financials, pharmaceuticals
TL;DR
RedHill Biopharma's 2024 20-F is in: $414.8M assets, $4.68M liabilities. Check it out.
AI Summary
RedHill Biopharma Ltd. filed its 20-F for the fiscal year ending December 31, 2024. The company, headquartered at 21 Ha'arba'a Street, Tel Aviv, Israel, operates in the Pharmaceutical Preparations sector. Key financial figures for 2024 include total assets of $414.8 million and total liabilities of $4.68 million. The filing also references various past agreements, including a U.S. Private Company Arrangement from March 30, 2015, and an Australian Asset Purchase Agreement from August 11, 2010.
Why It Matters
This filing provides investors with a comprehensive overview of RedHill Biopharma's financial health and operational status for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, RedHill Biopharma faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- $414.8B — Total Assets (Represents the company's total assets as of December 31, 2024.)
- $4.68M — Total Liabilities (Represents the company's total liabilities as of December 31, 2024.)
- 2024-12-31 — Reporting Period End Date (The end date for the financial information presented in the 20-F.)
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Filer of the 20-F
- 21 Ha'arba'a Street, Tel Aviv (location) — Company's business and mailing address
- 2024-12-31 (date) — End of the reporting period
- 414801000 (dollar_amount) — Total assets for the fiscal year 2024
- 4683000 (dollar_amount) — Total liabilities for the fiscal year 2024
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
- Daiichi Sankyo (company) — Mentioned in relation to Movantik
FAQ
What is RedHill Biopharma's primary business sector?
RedHill Biopharma Ltd. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code 2834.
What were RedHill Biopharma's total assets at the end of the 2024 fiscal year?
The company reported total assets of $414,801,000 (approximately $414.8 million) for the fiscal year ending December 31, 2024.
What were RedHill Biopharma's total liabilities at the end of the 2024 fiscal year?
The company reported total liabilities of $4,683,000 (approximately $4.68 million) for the fiscal year ending December 31, 2024.
When was the company's business address last updated in this filing?
The business address at 21 Ha'arba'a Street, Tel Aviv, is listed with a date as of change of 20250410.
Does the filing indicate any specific past agreements or arrangements?
Yes, the filing references several past arrangements including a U.S. Private Company Arrangement (2015-03-30), a German Publicly Traded Company Arrangement (2014-06-30), and an Australian Asset Purchase Agreement (2010-08-11).
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 10, 2025 regarding RedHill Biopharma Ltd. (RDHL).